Ready-to-use food (RUF) is increasingly used for nutritional therapy in HIV-infected individuals. However, practical guidance advising nutrition care to HIV-infected adolescents is lacking, so that little is known about the acceptability of such therapy in this vulnerable population.
This study assesses the overall acceptability and perception of a RUF-based therapy and risk factors associated with sub-optimal RUF intake in HIV-infected undernourished adolescents in Senegal.Participants 5 to 18 years of age with acute malnutrition were enrolled in 12 HIV clinics in Senegal. Participants were provided with imported RUF, according to WHO prescription weight- and age-bands (2009), until recovery or for a maximum of 9-12 months. Malnutrition and recovery were defined according to WHO growth standards.
Adherence was assessed fortnightly by self-reported RUF intake over the period. Sub-optimal RUF intake was defined as when consumption of the RUF provision was < 50%. RUF therapy acceptability and perceptions were assessed using a structured questionnaire at week 2 and focus group discussions (FGDs) at the end of the study. Factors associated with sub-optimal RUF intake at week 2 were identified using a stepwise logistic regression model.
We enrolled 173 participants, with a median age of 12.5 years (Interquartile range: 9.5-14.9), of whom 61% recovered from malnutrition within the study period.
Median follow-up duration was 66 days (21-224). RUF consumption was stable, varying between 64 and 57% of the RUF provided, throughout the follow-up. At week 2, sub-optimal RUF intake was observed in 31% of participants. Dislike of the taste of RUF (aOR = 5.0, 95% CI: 2.0-12.3), HIV non-disclosure (5.1, 1.9-13.9) and food insecurity (2.8, 1.1-7.2) were the major risk factors associated with sub-optimal RUF intake at week 2.
CD57 / B3GAT1 (Natural Killer Cell Marker); Clone NK-1 (Concentrate) |
|||
RA0356-C.1 | ScyTek Laboratories | 0.1 ml | 60.07 EUR |
CD57 / B3GAT1 (Natural Killer Cell Marker); Clone NK-1 (Concentrate) |
|||
RA0356-C.5 | ScyTek Laboratories | 0.5 ml | 158.6 EUR |
Monoclonal CD57 / B3GAT1 (Natural Killer Cell Marker) Antibody, Clone: NK/804 |
|||
AMM00761G | Leading Biology | 7 ml | 580.8 EUR |
Description: A Monoclonal antibody against Human CD57 / B3GAT1 (Natural Killer Cell Marker). The antibodies are raised in Mouse and are from clone NK/804. This antibody is applicable in IHC, IF |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) |
|||
MBS4380448-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | 230 EUR |
Granzyme B (NK/T-Cell Lymphoma Marker) |
|||
MBS4380448-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | 405 EUR |
Granzyme B (NK/T-Cell Lymphoma Marker) |
|||
MBS4380448-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | 405 EUR |
Granzyme B (NK/T-Cell Lymphoma Marker) |
|||
MBS4380448-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | 1725 EUR |
Granzyme B (NK/T-Cell Lymphoma Marker) |
|||
MBS4380448-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | 1725 EUR |
Granzyme B (NK/T-Cell Lymphoma Marker) |
|||
MBS4380968-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | 230 EUR |
Granzyme B (NK/T-Cell Lymphoma Marker) |
|||
MBS4380968-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | 405 EUR |
Granzyme B (NK/T-Cell Lymphoma Marker) |
|||
MBS4380968-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | 405 EUR |
Granzyme B (NK/T-Cell Lymphoma Marker) |
|||
MBS4380968-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | 1725 EUR |
Granzyme B (NK/T-Cell Lymphoma Marker) |
|||
MBS4380968-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | 1725 EUR |
Granzyme B (NK/T-Cell Lymphoma Marker) |
|||
MBS4380969-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | 230 EUR |
Granzyme B (NK/T-Cell Lymphoma Marker) |
|||
MBS4380969-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | 405 EUR |
Granzyme B (NK/T-Cell Lymphoma Marker) |
|||
MBS4380969-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | 405 EUR |
Granzyme B (NK/T-Cell Lymphoma Marker) |
|||
MBS4380969-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | 1725 EUR |
Granzyme B (NK/T-Cell Lymphoma Marker) |
|||
MBS4380969-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | 1725 EUR |
Granzyme B (NK/T-Cell Lymphoma Marker) |
|||
MBS4381698-05mL | MyBiosource | 0.5mL | 405 EUR |
Granzyme B (NK/T-Cell Lymphoma Marker) |
|||
MBS4381698-5x05mL | MyBiosource | 5x0.5mL | 1725 EUR |
Monoclonal CD57 / B3GAT1 (Natural Killer Cell Marker) Antibody, Clone: NK-1 |
|||
AMM00752G | Leading Biology | 7 ml | 580.8 EUR |
Description: A Monoclonal antibody against Human CD57 / B3GAT1 (Natural Killer Cell Marker). The antibodies are raised in Mouse and are from clone NK-1. This antibody is applicable in IHC, IF |
|||
CD57 / B3GAT1 (Natural Killer Cell Marker); Clone HNK-1 & NK-1 (Concentrate) |
|||
RA0357-C.1 | ScyTek Laboratories | 0.1 ml | 60.07 EUR |
CD57 / B3GAT1 (Natural Killer Cell Marker); Clone HNK-1 & NK-1 (Concentrate) |
|||
RA0357-C.5 | ScyTek Laboratories | 0.5 ml | 158.6 EUR |
293AD Cell Line |
|||
AD-100 | Cell Biolabs | 1 vial | 365 EUR |
293AAV Cell Line |
|||
AAV-100 | Cell Biolabs | 1 vial | 405 EUR |
293LTV Cell Line |
|||
LTV-100 | Cell Biolabs | 1 vial | 405 EUR |
293RTV Cell Line |
|||
RV-100 | Cell Biolabs | 1 vial | 405 EUR |
StemTAG Stem Cell Colony Formation Assay (Cell Recovery Compatible) |
|||
CBA-325 | Cell Biolabs | 96 assays | 1027.2 EUR |
Description: Our StemTAG 96-Well Stem Cell Colony Formation Assay provides a high-throughput method to quantify ES cells in just 7-10 days, and no manual cell counting is required. Once colonies are formed, they may be analyzed in three different ways: 1. Lyse cells, then quantify in a fluorescence plate reader using dye included in the kit; 2. Lyse cells, then quantify alkaline phosphatase activity using reagents provided; or 3. Recover colonies from matrix for further culture or analysis. |
|||
StemTAG Stem Cell Colony Formation Assay (Cell Recovery Compatible) |
|||
CBA-325-5 | Cell Biolabs | 5 x 96 assays | 4033.2 EUR |
Description: Our StemTAG 96-Well Stem Cell Colony Formation Assay provides a high-throughput method to quantify ES cells in just 7-10 days, and no manual cell counting is required. Once colonies are formed, they may be analyzed in three different ways: 1. Lyse cells, then quantify in a fluorescence plate reader using dye included in the kit; 2. Lyse cells, then quantify alkaline phosphatase activity using reagents provided; or 3. Recover colonies from matrix for further culture or analysis. |
|||
CytoSelectā¢ Cell Transformation Assay (Cell Recovery Compatible), Colorimetric |
|||
CBA-135 | Cell Biolabs | 96 assays | 715 EUR |
CytoSelectā¢ Cell Transformation Assay (Cell Recovery Compatible), Colorimetric |
|||
CBA-135-5 | Cell Biolabs | 5 x 96 assays | 3095 EUR |
CytoSelectā¢ Cell Transformation Assay (Cell Recovery Compatible), Fluorometric |
|||
CBA-140 | Cell Biolabs | 96 assays | 750 EUR |
CytoSelectā¢ Cell Transformation Assay (Cell Recovery Compatible), Fluorometric |
|||
CBA-140-5 | Cell Biolabs | 5 x 96 assays | 3215 EUR |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC041259-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF405S conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC041259-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF405S conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC881259-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF488A conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC881259-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF488A conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC801259-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF680 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC801259-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF680 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC811259-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF680R conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC811259-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF680R conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC941259-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF594 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC941259-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF594 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC431259-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF543 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC431259-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF543 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC401259-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF640R conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC401259-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF640R conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC471259-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF647 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC471259-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF647 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC051259-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF405M conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC051259-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF405M conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC551259-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF555 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC551259-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF555 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC701259-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF770 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC701259-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF770 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC611259-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF660R conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC611259-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF660R conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC681259-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF568 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNC681259-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF568 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNCP1259-250 | Biotium | 250uL | 459.6 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), PerCP conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNCR1259-250 | Biotium | 250uL | 459.6 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), RPE conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNUB1259-100 | Biotium | 100uL | 250.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Concentration: 0.2mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNUB1259-500 | Biotium | 500uL | 549.6 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Concentration: 0.2mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNCA1259-250 | Biotium | 250uL | 459.6 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), APC conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNCH1259-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNCH1259-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNCAP1259-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNCAP1259-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNCB1259-100 | Biotium | 100uL | 238.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Biotin conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNCB1259-500 | Biotium | 500uL | 652.8 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Biotin conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
BNUM1259-50 | Biotium | 50uL | 474 EUR |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), 1mg/mL |
|||
CD72 (B Cell Marker) |
|||
MBS4381445-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | 230 EUR |
CD72 (B Cell Marker) |
|||
MBS4381445-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | 405 EUR |
CD72 (B Cell Marker) |
|||
MBS4381445-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | 405 EUR |
CD72 (B Cell Marker) |
|||
MBS4381445-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | 1725 EUR |
CD72 (B Cell Marker) |
|||
MBS4381445-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | 1725 EUR |
Monoclonal CD57 / B3GAT1 (Natural Killer Cell Marker) Antibody, Clone: HNK-1 + NK-1 |
|||
AMM00758G | Leading Biology | 7 ml | 580.8 EUR |
Description: A Monoclonal antibody against Human CD57 / B3GAT1 (Natural Killer Cell Marker). The antibodies are raised in Mouse and are from clone HNK-1 + NK-1. This antibody is applicable in IHC, IF |
|||
293/GFP Cell Line |
|||
AKR-200 | Cell Biolabs | 1 vial | 460 EUR |
T47D/GFP Cell Line |
|||
AKR-208 | Cell Biolabs | 1 vial | 686.4 EUR |
Description: T47D/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
A549/GFP Cell Line |
|||
AKR-209 | Cell Biolabs | 1 vial | 460 EUR |
HeLa/GFP Cell Line |
|||
AKR-213 | Cell Biolabs | 1 vial | 460 EUR |
293/Cas9 Cell Line |
|||
AKR-5110 | Cell Biolabs | 1 vial | 460 EUR |
HeLa/Cas9 Cell Line |
|||
AKR-5111 | Cell Biolabs | 1 vial | 460 EUR |
NIH3T3/GFP Cell Line |
|||
AKR-214 | Cell Biolabs | 1 vial | 460 EUR |
Plasma Cell Marker (AP) |
|||
MBS6122405-01mL | MyBiosource | 0.1(mL | 935 EUR |
Plasma Cell Marker (AP) |
|||
MBS6122405-5x01mL | MyBiosource | 5x0.1mL | 4050 EUR |
Plasma Cell Marker (PE) |
|||
MBS6122410-01mL | MyBiosource | 0.1(mL | 935 EUR |
Plasma Cell Marker (PE) |
|||
MBS6122410-5x01mL | MyBiosource | 5x0.1mL | 4050 EUR |
BMI1 (Stem Cell Marker) |
|||
MBS4380690-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | 230 EUR |
BMI1 (Stem Cell Marker) |
|||
MBS4380690-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | 405 EUR |
BMI1 (Stem Cell Marker) |
|||
MBS4380690-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | 405 EUR |
BMI1 (Stem Cell Marker) |
|||
MBS4380690-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | 1725 EUR |
BMI1 (Stem Cell Marker) |
|||
MBS4380690-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | 1725 EUR |
CD29 (Stem Cell Marker) |
|||
MBS4381028-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | 230 EUR |
CD29 (Stem Cell Marker) |
|||
MBS4381028-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | 405 EUR |
CD29 (Stem Cell Marker) |
|||
MBS4381028-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | 405 EUR |
CD29 (Stem Cell Marker) |
|||
MBS4381028-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | 1725 EUR |
CD29 (Stem Cell Marker) |
|||
MBS4381028-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | 1725 EUR |
CD29 (Stem Cell Marker) |
|||
MBS4381580-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | 230 EUR |
CD29 (Stem Cell Marker) |
|||
MBS4381580-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | 405 EUR |
CD29 (Stem Cell Marker) |
|||
MBS4381580-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | 405 EUR |
CD29 (Stem Cell Marker) |
|||
MBS4381580-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | 1725 EUR |
CD29 (Stem Cell Marker) |
|||
MBS4381580-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | 1725 EUR |
NIH3T3/Cas9 Cell Line |
|||
AKR-5104 | Cell Biolabs | 1 vial | 460 EUR |
CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Colorimetric, Trial Size |
|||
CBA-135-T | Cell Biolabs | 24 assays | 518.4 EUR |
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cellsĀ using the included fluorescent dye, or recover the cells for further analysis. |
|||
Myeloid Cell Marker (AP) |
|||
MBS6124390-01mL | MyBiosource | 0.1(mL | 935 EUR |
Myeloid Cell Marker (AP) |
|||
MBS6124390-5x01mL | MyBiosource | 5x0.1mL | 4050 EUR |
Myeloid Cell Marker (PE) |
|||
MBS6124395-01mL | MyBiosource | 0.1(mL | 935 EUR |
Myeloid Cell Marker (PE) |
|||
MBS6124395-5x01mL | MyBiosource | 5x0.1mL | 4050 EUR |
Myeloid Cell Marker (AP) |
|||
MBS6123509-01mL | MyBiosource | 0.1(mL | 935 EUR |
Myeloid Cell Marker (AP) |
|||
MBS6123509-5x01mL | MyBiosource | 5x0.1mL | 4050 EUR |
Myeloid Cell Marker (PE) |
|||
MBS6123514-01mL | MyBiosource | 0.1(mL | 935 EUR |
Myeloid Cell Marker (PE) |
|||
MBS6123514-5x01mL | MyBiosource | 5x0.1mL | 4050 EUR |
Plasma Cell Marker (APC) |
|||
MBS6122406-01mL | MyBiosource | 0.1(mL | 935 EUR |
Plasma Cell Marker (APC) |
|||
MBS6122406-5x01mL | MyBiosource | 5x0.1mL | 4050 EUR |
Plasma Cell Marker (HRP) |
|||
MBS6122409-01mL | MyBiosource | 0.1(mL | 935 EUR |
Plasma Cell Marker (HRP) |
|||
MBS6122409-5x01mL | MyBiosource | 5x0.1mL | 4050 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4380289-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | 230 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4380289-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | 405 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4380289-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | 405 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4380289-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | 1725 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4380289-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | 1725 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4380290-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | 230 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4380290-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | 405 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4380290-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | 405 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4380290-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | 1725 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4380290-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | 1725 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4380719-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | 230 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4380719-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | 405 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4380719-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | 405 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4380719-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | 1725 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4380719-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | 1725 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4381344-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | 230 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4381344-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | 405 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4381344-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | 405 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4381344-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | 1725 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4381344-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | 1725 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4381345-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | 230 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4381345-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | 405 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4381345-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | 405 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4381345-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | 1725 EUR |
PAX8 (Renal Cell Marker) |
|||
MBS4381345-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | 1725 EUR |
Myeloid Cell Marker (APC) |
|||
MBS6124391-01mL | MyBiosource | 0.1(mL | 935 EUR |
Myeloid Cell Marker (APC) |
|||
MBS6124391-5x01mL | MyBiosource | 5x0.1mL | 4050 EUR |
Myeloid Cell Marker (HRP) |
|||
MBS6124394-01mL | MyBiosource | 0.1(mL | 935 EUR |
Myeloid Cell Marker (HRP) |
|||
MBS6124394-5x01mL | MyBiosource | 5x0.1mL | 4050 EUR |
Myeloid Cell Marker (APC) |
|||
MBS6123510-01mL | MyBiosource | 0.1(mL | 935 EUR |
Myeloid Cell Marker (APC) |
|||
MBS6123510-5x01mL | MyBiosource | 5x0.1mL | 4050 EUR |
Myeloid Cell Marker (HRP) |
|||
MBS6123513-01mL | MyBiosource | 0.1(mL | 935 EUR |
Myeloid Cell Marker (HRP) |
|||
MBS6123513-5x01mL | MyBiosource | 5x0.1mL | 4050 EUR |
Plasma Cell Marker (FITC) |
|||
MBS6122408-01mL | MyBiosource | 0.1(mL | 935 EUR |
Plasma Cell Marker (FITC) |
|||
MBS6122408-5x01mL | MyBiosource | 5x0.1mL | 4050 EUR |
MCF-7/Luc Cell Line |
|||
AKR-234 | Cell Biolabs | 1 vial | 686.4 EUR |
Description: MCF-7/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line. |
|||
Myeloid Cell Marker (FITC) |
|||
MBS6124393-01mL | MyBiosource | 0.1(mL | 935 EUR |
Myeloid Cell Marker (FITC) |
|||
MBS6124393-5x01mL | MyBiosource | 5x0.1mL | 4050 EUR |
Myeloid Cell Marker (FITC) |
|||
MBS6123512-01mL | MyBiosource | 0.1(mL | 935 EUR |
Myeloid Cell Marker (FITC) |
|||
MBS6123512-5x01mL | MyBiosource | 5x0.1mL | 4050 EUR |
SKOV-3/Luc Cell Line |
|||
AKR-232 | Cell Biolabs | 1 vial | 686.4 EUR |
Description: SKOV-3/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line. |
|||
OVCAR-5/RFP Cell Line |
|||
AKR-254 | Cell Biolabs | 1 vial | 686.4 EUR |
Description: OVCAR-5/RFP Cell Line stably expresses RFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
Plasma Cell Marker (Biotin) |
|||
MBS6122407-01mL | MyBiosource | 0.1(mL | 935 EUR |
Plasma Cell Marker (Biotin) |
|||
MBS6122407-5x01mL | MyBiosource | 5x0.1mL | 4050 EUR |
Desmin (Muscle Cell Marker) |
|||
MBS439907-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | 230 EUR |
Desmin (Muscle Cell Marker) |
|||
MBS439907-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | 405 EUR |
Desmin (Muscle Cell Marker) |
|||
MBS439907-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | 405 EUR |
Desmin (Muscle Cell Marker) |
|||
MBS439907-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | 1725 EUR |
Desmin (Muscle Cell Marker) |
|||
MBS439907-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | 1725 EUR |
Tryptase (Mast Cell Marker) |
|||
MBS4380509-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | 230 EUR |
Tryptase (Mast Cell Marker) |
|||
MBS4380509-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | 405 EUR |
Tryptase (Mast Cell Marker) |
|||
MBS4380509-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | 405 EUR |
Tryptase (Mast Cell Marker) |
|||
MBS4380509-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | 1725 EUR |
Tryptase (Mast Cell Marker) |
|||
MBS4380509-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | 1725 EUR |
Desmin (Muscle Cell Marker) |
|||
MBS4380542-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | 230 EUR |
Desmin (Muscle Cell Marker) |
|||
MBS4380542-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | 405 EUR |
Desmin (Muscle Cell Marker) |
|||
MBS4380542-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | 405 EUR |
Desmin (Muscle Cell Marker) |
|||
MBS4380542-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | 1725 EUR |
Desmin (Muscle Cell Marker) |
|||
MBS4380542-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | 1725 EUR |
Desmin (Muscle Cell Marker) |
|||
MBS4380835-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | 230 EUR |
Desmin (Muscle Cell Marker) |
|||
MBS4380835-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | 405 EUR |
Desmin (Muscle Cell Marker) |
|||
MBS4380835-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | 405 EUR |
Desmin (Muscle Cell Marker) |
|||
MBS4380835-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | 1725 EUR |
Desmin (Muscle Cell Marker) |
|||
MBS4380835-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | 1725 EUR |
Tryptase (Mast Cell Marker) |
|||
MBS4381312-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | 230 EUR |
Tryptase (Mast Cell Marker) |
|||
MBS4381312-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | 405 EUR |
Tryptase (Mast Cell Marker) |
|||
MBS4381312-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | 405 EUR |
Tryptase (Mast Cell Marker) |
|||
MBS4381312-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | 1725 EUR |
Tryptase (Mast Cell Marker) |
|||
MBS4381312-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | 1725 EUR |
CytoSelect 96-Well Cell Transformation Assay (Cell Recovery Compatible, Fluorometric), Trial Size |
|||
CBA-140-T | Cell Biolabs | 24 assays | 547.2 EUR |
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cellsĀ using the included fluorescent dye, or recover the cells for further analysis. |
|||
Myeloid Cell Marker (Biotin) |
|||
MBS6124392-01mL | MyBiosource | 0.1(mL | 935 EUR |
FGDs showed that the need to hide from others to avoid sharing and undesirable effects were other constraints on RUF feeding.This study revealed several factors reducing the acceptability and adherence to RUF therapy based on WHO guidelines in HIV-infected adolescents.
Tailoring prescription guidance and empowering young patients in their care are crucial levers for improving the acceptability of RUF-based therapy in routine care.ClinicalTrials.gov identifier